Benzinga | Oct 5, 2021 09:01AM EDT

Celsion Corporation Announces New Management Appointments

Celsion Corporation (NASDAQ:CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces the strengthening of its management team with a new hire and a promotion in its vaccine development program, and the hiring of a veteran clinical trial project manager for its Phase II GEN-1 immunotherapy study in advanced ovarian cancer. These changes all are effective immediately and are as follows:

* Carlo Iavarone, Ph.D. joins as Senior Director, Non-Clinical Research

* Subeena Sood, Ph.D. promoted to Senior Manager, Biology and Preclinical Studies

* Beth J. Llewellyn joins as Director of Clinical Operations